Sunderic Kristifor, Wright Andrew M, Kleinstreuer Nicole, Ledbetter Victoria, Milora Katelynn A, Happel Christine, Shaughnessy Daniel, Johnstone Chariz P, Casco Daniel Anthony, Macioce Nikeya, Marzec Jacqui, Kano Kristin, Ochocinska Margaret J, Tagle Danilo A
National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.
Office of the Director, National Institutes of Health, Bethesda, MD 20892, USA.
NAM J. 2025;1. doi: 10.1016/j.namjnl.2025.100026. Epub 2025 May 17.
New approach methodologies (NAMs) are proving to be invaluable tools in basic and clinical research to better understand human health and disease, elucidate mechanisms, and study the efficacy and toxicity of novel therapeutics that can improve upon and complement animal-based methodologies. Over the last 15 years, the National Institutes of Health (NIH) has increased investment in NAMs, including in chemico, in silico, and in vitro approaches, such as cell-free assay systems, digital twins, and microphysiological systems (MPS). To further catalyze and innovate the use of NAMs, the NIH Common Fund has initiated a new program, Complement Animal Research In Experimentation (Complement-ARIE), which aims to pioneer the development, standardization, validation, and regulatory use of combinatorial NAMs that will more accurately model human biology and disease states. This program specifically aims to 1) better model human health and disease differences in outcomes across populations, 2) develop NAMs that can provide insights into specific biological processes or disease states, 3) validate mature NAMs to support regulatory use and standardization, and 4) complement traditional animal models to make research more efficient and effective. To inform the implementation of Complement-ARIE, the NIH organized strategic planning activities including an inter-agency retreat, public listening sessions, scientific literature landscape analysis, and a challenge prize. Here we discuss the goals and findings of these activities, and how these results helped identify and address scientific and operational opportunities and roadblocks for implementation of the program towards broader acceptance and impact of NAMs. We anticipate these new methods and approaches could transform the way we do basic, translational, and clinical sciences.
新方法学(NAMs)已被证明是基础研究和临床研究中非常有价值的工具,有助于更好地理解人类健康与疾病、阐明机制,并研究新型疗法的疗效和毒性,这些疗法能够改进并补充基于动物的方法学。在过去15年里,美国国立卫生研究院(NIH)增加了对NAMs的投资,包括化学、计算机模拟和体外方法,如无细胞检测系统、数字孪生和微生理系统(MPS)。为了进一步推动和创新NAMs的应用,NIH共同基金启动了一个新项目,即实验中补充动物研究(Complement-ARIE),旨在开创组合式NAMs的开发、标准化、验证及监管应用,从而更准确地模拟人类生物学和疾病状态。该项目具体目标包括:1)更好地模拟不同人群在健康和疾病结果方面的差异;2)开发能够深入了解特定生物过程或疾病状态的NAMs;3)验证成熟的NAMs以支持监管应用和标准化;4)补充传统动物模型,使研究更高效、更有效。为指导Complement-ARIE的实施,NIH组织了战略规划活动,包括跨部门务虚会、公众听证会、科学文献综述分析以及一项挑战奖。在此,我们讨论这些活动的目标和结果,以及这些结果如何帮助识别和解决科学及操作方面的机遇与障碍,以推动该项目的实施,使NAMs得到更广泛的接受和产生更大影响。我们预计这些新方法和途径可能会改变我们开展基础科学、转化科学和临床科学研究的方式。